Helfand BT - Search Results

1

Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Cooley LF, et al. Among authors: helfand bt. J Urol. 2021 Nov;206(5):1156. doi: 10.1097/JU.0000000000001937.02. Epub 2021 Sep 10. J Urol. 2021. PMID: 34503354 No abstract available.

2

Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ. Meeks JJ, et al. Among authors: helfand bt. J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289590 Clinical Trial.

3

Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.

Loeb S, Roehl KA, Helfand BT, Catalona WJ. Loeb S, et al. Among authors: helfand bt. Urology. 2008 Oct;72(4):887-91. doi: 10.1016/j.urology.2007.12.016. Epub 2008 Mar 10. Urology. 2008. PMID: 18329080

4

Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ. Helfand BT, et al. J Urol. 2008 Jun;179(6):2197-201; discussion 2202. doi: 10.1016/j.juro.2008.01.110. Epub 2008 Apr 18. J Urol. 2008. PMID: 18423739

5

Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, Catalona WJ. Helfand BT, et al. BJU Int. 2009 Aug;104(3):304-9. doi: 10.1111/j.1464-410X.2009.08421.x. Epub 2009 Feb 23. BJU Int. 2009. PMID: 19239451

6

Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.

Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, Catalona WJ. Meeks JJ, et al. Among authors: helfand bt. J Urol. 2009 Jun;181(6):2515-8; discussion 2518-9. doi: 10.1016/j.juro.2009.01.102. Epub 2009 Apr 16. J Urol. 2009. PMID: 19371879 Free PMC article.

7

Pathological outcomes associated with the 17q prostate cancer risk variants.

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, Catalona WJ. Helfand BT, et al. J Urol. 2009 Jun;181(6):2502-7. doi: 10.1016/j.juro.2009.01.109. Epub 2009 Apr 16. J Urol. 2009. PMID: 19371897 Free PMC article.

8

Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.

Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, Catalona WJ, Lee C. Zhang Q, et al. Among authors: helfand bt. Clin Cancer Res. 2009 May 15;15(10):3557-67. doi: 10.1158/1078-0432.CCR-08-1656. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447876

9

Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?

Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ. Loeb S, et al. Among authors: helfand bt. BJU Int. 2009 Nov;104(9):1200-3. doi: 10.1111/j.1464-410X.2009.08656.x. Epub 2009 Jul 20. BJU Int. 2009. PMID: 19627283 Free PMC article.

10

Is statin use associated with prostate cancer aggressiveness?

Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Loeb S, et al. Among authors: helfand bt. BJU Int. 2010 May;105(9):1222-5. doi: 10.1111/j.1464-410X.2009.09007.x. Epub 2009 Nov 3. BJU Int. 2010. PMID: 19888973 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page